Paolo M. Comoglio - Concepedia

Author

Paolo M. Comoglio

Also Known As

COMOGLIO P. M., Comoglio, Paolo, P COMOGLIO, P Comoglio, P M Comoglio, P. Comoglio, P. M. COMOGLIO, P. M. Comoglio, P.M. COMOGLIO, P.M. Comoglio

751

Publications

45.7K

Citations

115

H-Index

201

Concepts

All Affiliations

University of Turin Candiolo Cancer Institute Istituti di Ricovero e Cura a Carattere Scientifico Department of Medical Sciences IRCCS Ospedale San Raffaele

About

Paolo M. Comoglio is an author at University of Turin specializing in medicine, cell biology, and cell signaling.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	82	169	25.5K
2	Health Sciences	23	24	5.5K
3	Natural Sciences	20	22	3.6K
4	Engineering	4	4	744
5	Social Sciences	1	1	460

Paolo M. Comoglio

294

Publications

37.6K

Citations

105

H-Index

Page 1

	Year	Citations
Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. Federico Bussolino, Maria Flavia Di Renzo, Marina Ziche, The Journal of Cell Biology Endothelial CellsImmunologySub-nanomolar ConcentrationsCellular PhysiologyHepatocyte Growth Factor	1992	1.3K
Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene Selma Pennacchietti, Paolo Michieli, Massimiliano Mazzone, Cancer Cell Transcriptional RegulationDevelopmental BiologyInvasive GrowthRedox RegulatorHypoxia (Medicine)	2003	1.3K
Plexins Are a Large Family of Receptors for Transmembrane, Secreted, and GPI-Anchored Semaphorins in Vertebrates Luca Tamagnone, Stefania Artigiani, Hang Chen, Cell Signal TransductionBiochemistryG Protein-coupled ReceptorNatural SciencesLarge Family	1999	1.1K
A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family Carola Ponzetto, Alberto Bardelli, Zhen Zhu, Cell Signal TransductionSignaling PathwayMedicineLiver PhysiologyReceptor Tyrosine Kinase	1994	987
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial Andrea Sartore‐Bianchi, Livio Trusolino, Cosimo Martino, The Lancet Oncology OncologyMedicinePathologyColorectal CancerDual-targeted Therapy	2016	984
A Molecularly Annotated Platform of Patient-Derived Xenografts (“Xenopatients”) Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer Andrea Bertotti, Giorgia Migliardi, Francesco Galimi, Cancer Discovery	2011	938
Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-MET. Luigi Naldini, Elisa Vigna, Radha P. Narsimhan, PubMed	1991	700
Amplification of the <i>MET</i> Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer Alberto Bardelli, Simona Corso, Andrea Bertotti, Cancer Discovery EngineeringPathologyCancer BiologyTumor BiologyCancer Cell Biology	2013	654
Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor. Luigi Naldini, Luca Tamagnone, Elisa Vigna, The EMBO Journal Protein FunctionSignal TransductionBiochemistryLiver PhysiologyExtracellular Proteolytic Cleavage	1992	562
Regulation of Scatter Factor/Hepatocyte Growth Factor Responses by Ras, Rac, and Rho in MDCK Cells Anne J. Ridley, Paolo M. Comoglio, Alan Hall Molecular and Cellular Biology Cell AdhesionCell ProliferationCytoskeletonCell GrowthCell Colonies	1995	535

Page 1